Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$31.32 USD
+1.64 (5.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.32 USD
+1.64 (5.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
by Zacks Equity Research
Surging implied volatility makes Celldex Therapeutics (CLDX) stock lucrative to the option traders.
Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.
Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation
by Zacks Equity Research
AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.
Amgen Announces Acceptance of MAA for Evenity in Europe
by Zacks Equity Research
Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio
by Zacks Equity Research
Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.
Shire's New Formulation of Oncaspar Gets Approval in Europe
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
Glaxo's Nucala Label Expansion Application Gets FDA Approval
by Zacks Equity Research
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
by Zacks Equity Research
Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Celldex Ends Phase II Enrollment for Breast Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.
Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).